3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Glioma
1
Exanthema
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diarrhea
1
Interventions
Rituximab
117
Cyclophosphamide
104
fludarabine phosphate
52
Peripheral Blood Stem Cell Transplantation
52
Cytarabine
47
Etoposide
44
Mycophenolic Acid
41
Filgrastim
40
Whole-Body Irradiation
37
Tacrolimus
36
Melphalan
35
Bortezomib
34
Methotrexate
33
Cyclosporine
33
Busulfan
31
Radiotherapy
30
Vincristine
28
Doxorubicin
27
Dexamethasone
27
Carmustine
25
Antilymphocyte Serum
25
Lenalidomide
23
Bendamustine Hydrochloride
23
ibrutinib
22
Granulocyte Colony-Stimulating Factor
20
obinutuzumab
18
fludarabine
18
acalabrutinib
18
Prednisone
18
venetoclax
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Mantle-Cell
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts